Results 261 to 270 of about 122,310 (350)

Discordant cerebrospinal fluid and positron emission tomography amyloid biomarkers in an APP mutation carrier presenting corticobasal syndrome. [PDF]

Alzheimers Dement
Liu FT, Li XY, Lu JY, Zuo CT.
europepmc   +1 more source

Relationship of cholinergic basal forebrain atrophy with the time course of Alzheimer's disease pathology and cognitive decline in adults with Down syndrome: a longitudinal cohort study

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Adults with Down syndrome (DS) display increased Alzheimer's disease (AD) risk. The cholinergic system declines early in the AD continuum and relates to cognitive and functional decline. We aimed to identify the timeline of cholinergic decline in relation to hippocampal atrophy within the AT(N) framework in DS.
Jason K. Russell, Zinayida Schlachetzki, Alexander C. Conley, Brian D. Boyd, Paul A. Newhouse, Paul S. Aisen, Michael S. Rafii, for the Alzheimer's Biomarker Consortium on Down Syndrome Study   +7 more
wiley   +1 more source

Aquaporin‐4 and caveolin‐1 as mediators of fibrinogen‐driven cerebrovascular pathology in cerebral amyloid angiopathy

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA), marked by amyloid beta (Aβ) accumulation in perivascular spaces (PVSs), contributes to vascular injury and inflammation in Alzheimer's disease. The mechanisms underlying CAA‐related vascular pathology remain unclear.
Vishal Singh, Nicholas Rochakim, Francesca Ferraresso, Khushi Garg, Asma B. Rizvi, Arnab Choudhury, Christian J. Kastrup, Hyung Jin Ahn   +7 more
wiley   +1 more source

APP family is a regulator of endo-lysosomal membrane vulnerability. [PDF]

J Biol Chem
Lundin B, Wieckiewicz N, Yokomizo M, Sadek M, Kwarteng DO, Dickson JR, Sobolewski RGR, Derosla V, Armagan G, Perrin F, Hyman BT, Berezovska O, Maesako M.   +12 more
europepmc   +1 more source

Gray matter microstructure from in vivo diffusion magnetic resonance imaging reflects post mortem neuropathology severity and clinical progression of Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Diffusion‐weighted imaging derived mean diffusivity (MD) correlates with Alzheimer's disease (AD) biomarkers, yet its neuropathological correlates remain unclear. METHODS Diffusion‐weighted imaging, post mortem neuropathology, and cognitive performance data were obtained from the National Alzheimer's Coordinating Center (N = 97 ...
Zaki Alasmar, Cécilia Tremblay, Roqaie Moqadam, Geidy E Serrano, Thomas G Beach, Alireza Atri, Yi Su, for the Alzheimer's Disease Neuroimaging Initiative, Yashar Zeighami, Mahsa Dadar   +9 more
wiley   +1 more source

Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible
Stephanie A. Schultz, Yiwen Rao, Lei Liu, Beth Ostaszewski, Amirah K. Anderson, Wai‐Ying Wendy Yau, Zahra Shirzadi, Brian A. Gordon, Jason Hassenstab, John C. Morris, Richard J. Perrin, Ricardo F. Allegri, Nicolas R. Barthélemy, Nick Fox, Gregory S. Day, Mathias Jucker, Allan I. Levey, Johannes Levin, Hiroshi Mori, Stephen Salloway, Peter Schofield, Eric McDade, Reisa A. Sperling, Randall J. Bateman, Dennis J. Selkoe, Jasmeer P. Chhatwal, and the Dominantly Inherited Alzheimer's Network   +26 more
wiley   +1 more source

Direct and indirect role of non-coding RNAs in company with amyloid and tau protein in promoting neuroinflammation in post-ischemic brain neurodegeneration. [PDF]

Front Cell Neurosci
Pluta R.
europepmc   +1 more source